EziSurg Medical Co., Ltd. was established in November 2011 in Shanghai, specializes in the R&D and industrialization of premium Minimally Invasive Surgery solutions worldwide. With a highly competitive product portfolio including surgical stapling series, surgical energy platform and surgical endoscopy platform, EziSurg is committed to improving surgical outcomes in general, bariatric, thoracic, colorectal, urinary and respiratory procedures, supplying medical professionals and treating patients home and abroad.

By the end of 2022, EziSurg’s products have been used in more than 1,000 hospitals across China, of which Grade 3A hospitals account for more than 40%, and have become the industry leader among domestic brands in the field of minimally invasive surgery solutions in China. In the overseas market, Ezisurg has established global subsidiaries in the United States and the Netherlands, get 155 global certifications including 7 FDA approvals and 14 CE marks, and get entry approval of more than 70 countries and regions in the world.